红日药业: 监事会决议公告

Core Viewpoint - The announcement details the resolutions passed during the second meeting of the ninth Supervisory Board of Tianjin Hongri Pharmaceutical Co., Ltd., which includes the approval of the 2025 semi-annual report and related financial matters [2][3][4]. Group 1: Meeting Details - The second meeting of the ninth Supervisory Board was held on August 26, 2025, in Tianjin, with all three supervisors present, including two participating via remote voting [2]. - The meeting was conducted in accordance with relevant laws, regulations, and the company's articles of association [2]. Group 2: Resolutions Passed - The Supervisory Board unanimously approved the 2025 semi-annual report and its summary, confirming that the report accurately reflects the company's operational status without any false statements or omissions [2][3]. - The board also approved the special report on the storage and use of raised funds, affirming that the procedures followed comply with regulatory requirements and there were no violations in the use of these funds [3]. - Additionally, the board agreed on the provision for asset impairment, stating that the decision adhered to the principle of prudence and was in line with accounting standards and company policies, ensuring no harm to the interests of shareholders [3][4].